Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Lei Cai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3489-4386; OpenAlex author ID A5101955979, A5134536799. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 10

  1. Targeting tumor-associated macrophages in pancreatic cancer. Last author DOI 10.1016/j.iliver.2026.100243↗
  2. SLC6A14-mediated carnitine transmembrane uptake from PPARγ+ cancer-associated fibroblasts promotes recurrence of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2025-336116↗
  3. A novel protein cPFKFB4 encoded by hsa_circ_0065394 strengthens PKM2-mediated glucose metabolic reprogramming to facilitate pancreatic cancer progression under… Co-author DOI 10.1186/s12943-025-02500-w↗
  4. Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216713↗
  5. Increased expression of miR-194-5p through the circPVRL3/miR-194-5p/SOCS2 axis promotes proliferation and metastasis in pancreatic ductal adenocarcinoma by act… Co-author DOI 10.1186/s12935-022-02835-0↗
  6. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. First author DOI 10.1093/jnci/djaa073↗
  7. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000002600↗
  8. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Co-author DOI 10.1016/j.canlet.2017.08.028↗
  9. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.16841↗
  10. Fyn requires HnRNPA2B1 and Sam68 to synergistically regulate apoptosis in pancreatic cancer. First author DOI 10.1093/carcin/bgr088↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fuming Xie · 3 shared papers, 2022–2026 · strength 0.70
  2. Yuxi Long · 2 shared papers, 2025–2026 · strength 0.56
  3. Theodoros P. Michelakos · 5 shared papers, 2017–2024 · strength 0.46
  4. Vikram Deshpande · 4 shared papers, 2017–2024 · strength 0.41
  5. Soldano Ferrone · 4 shared papers, 2017–2024 · strength 0.39
  6. Jingyang Yin · 2 shared papers, 2022–2025 · strength 0.37
  7. Huaizhi Wang · 2 shared papers, 2022–2025 · strength 0.37
  8. Jianyou Gu · 2 shared papers, 2022–2026 · strength 0.36
  9. Shixiang Guo · 2 shared papers, 2022–2026 · strength 0.36
  10. Luoyingzi Xie · 1 shared paper, 2026 · strength 0.33
  11. Cristina Rosa Ferrone · 4 shared papers, 2017–2021 · strength 0.29
  12. Xinhui Wang · 3 shared papers, 2017–2024 · strength 0.29
  13. David Tsai Ting · 2 shared papers, 2021–2024 · strength 0.27
  14. Hang Chen · 1 shared paper, 2025 · strength 0.23
  15. Pijiang Sun · 1 shared paper, 2026 · strength 0.23
  16. Junfeng Zhang · 1 shared paper, 2026 · strength 0.23
  17. Ashok Kumar Saluja · 1 shared paper, 2026 · strength 0.23
  18. Theodore Sunki Hong · 3 shared papers, 2017–2021 · strength 0.22
  19. Keith D. Lillemoe · 3 shared papers, 2017–2021 · strength 0.22
  20. Andrew Louis Warshaw · 2 shared papers, 2019–2021 · strength 0.17
  21. David P. Ryan · 2 shared papers, 2019–2021 · strength 0.17
  22. Motaz Qadan · 2 shared papers, 2019–2021 · strength 0.17
  23. Jennifer Yon-Li Wo · 2 shared papers, 2019–2021 · strength 0.17
  24. Yurie Sekigami · 1 shared paper, 2024 · strength 0.17
  25. Cristina R. Ferrone · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.